Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
automated, batch, blinded, breast, carcinoma, CASL, characterization, chemokine, chemoresistance, CHMP, colorectal, compound, concept, CRC, culture, driver, EC, exempt, exhibited, family, FFS, free, functional, immunologic, inspired, lung, margin, memory, monotherapy, murine, myeloid, naked, NSCLC, NTAP, pancreatic, pembrolizumab, PIPEDA, polymerase, PrEP, provincial, Quantitative, reaction, reactivation, receptor, renal, robust, save, shifted, shipment, signaling, simultaneously, symptomatic, thereto, transcriptase, transferee, Unremediated, URT, vial, Wilcoxon
Removed:
conspiracy, endpoint, fragment, open, transform
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view